Cipla eyes global on-ground presence with US, Brazil, Turkey on radar
This article was originally published in Scrip
More details of the strategic evolution underway at Cipla, traditionally known for its risk-averse global partnerships-only approach and lack of off-shore presence despite its products being available worldwide, are emerging. The Indian firm has now indicated its intent for its own set-up in the US and an expansion across a clutch of smaller markets.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.